Q32 Bio Inc.
QTTB
Get informed when a big investor buys or sells
+ FollowMarket Cap$141.18M
Close$
$2.25
81.5% downside
Current Fair Value
81.5% downsideOvervalued by 81.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $141.18 Million |
|---|---|
| Enterprise Value | $101.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.42 |
| Beta | -1.27 |
| Outstanding Shares | 14,095,371 |
Return
| Return on Equity | 71.78% |
|---|---|
| Return on Assets | 52.21% |
| Return on Invested Capital | 40.54% |
Valuation & Multiples
| P/E Ratio | 4.69 |
|---|---|
| PEG | -15.1 |
| Price to Sales | 4.06 |
| Price to Book Ratio | 4.06 |
| Enterprise Value to Revenue | 1.89 |
| Enterprise Value to EBIT | 4.72 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.57
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.65%▲ 10.94% |
|---|---|
| Total Invested | $60.62M▲ 127.38% |
| Investors Holding | 53▲ 2.00% |
ESG Score
No data
About Q32 Bio Inc.
131 employees
CEO: Arthur Tzianabos homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.